n
a
v
Portfolio
Genetics
AmplideX® Fragile X Dx & Carrier Screen Kit
AmplideX® mPCR FMR1 Kit
AmplideX® PCR/CE FMR1 Kit
AmplideX® FMR1 Controls
Xpansion Interpreter®
AmplideX® PCR/CE
SMN1/2
Plus Kit
AmplideX® PCR/CE
CFTR
Kit
AmplideX® PCR/CE C9orf72 Kit
AmplideX® PCR/CE
DMPK
Kit
AmplideX® PCR/CE
HTT
Kit
AmplideX® TRIO
Oncology
QuantideX® qPCR BCR-ABL IS Kit
QuantideX® qPCR BCR-ABL minor Kit
MolecularDx Controls
Catalog of Armored Products
SARS CoV-2 Controls
Made-To-Order Armored and Nucleic Acid
Molecular Assay Reagents
Custom & Companion Diagnostics
Partnered R&D
CAP-Accredited CLIA Lab
CTA Testing Site
Validated Platforms & Assays
Companion Diagnostics
Enabling Technologies
Assay Chemistries
Bioinformatics
Product Development Process
Resources
Publications
Articles
Whitepapers
Posters
Disease Information
Fragile X Syndrome
Dementia
Chronic Myeloid Leukemia (CML)
Other Resources
Videos
Carrier Screening Guide
Safety Data Sheets
Sales Contacts
Our Culture
Employee Spotlights
Culture & Heritage
Sales Contacts
About
Leadership Team
Culture and Heritage
News
Upcoming Events
Business Development
Contact
Careers
Search
News
Home
News
Press Releases
Year
Select Year
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
November 11, 2013
Asuragen to present at upcoming Association for Molecular Pathology Annual Meeting on Genomic Medicine
Share
October 8, 2013
Asuragen Receives Notice of Patent Allowance for Broad Diagnostic Application of miR-21 in Cancer
Share
May 30, 2013
Asuragen launches SuraSeq™ Next Generation Sequencing Panel in its CAP accredited CLIA Laboratory
Share
April 23, 2013
Asuragen announces publication on standardization of BCR-ABL1 testing on the international scale
Share
April 4, 2013
Asuragen launches SuraSeq™ Next Generation Sequencing Service
Share
March 21, 2013
Study Finds New Genetic Test Better Predicts Mother’s Risk of Having a Child With Fragile X Syndrome
Share
February 12, 2013
Asuragen presents data on next generation sequencing of FFPE tumor samples at Molecular Medicine Tri-Conference 2013
Share
January 7, 2013
Rolland Carlson, Ph.D. named CEO of Asuragen
Share
October 24, 2012
Asuragen to present at upcoming Association for Molecular Pathology Annual Meeting on Genomic Medicine
Share
March 30, 2012
Asuragen awarded $6.8 million commercialization award from the Cancer Prevention and Research Institute of Texas
Share
Prev
1
…
4
5
6
7
8
Next
About
About
Leadership Team
Culture and Heritage
News
Upcoming Events
Business Development
Back To
Top
